EP Wealth Advisors LLC Purchases New Holdings in Hologic, Inc. (NASDAQ:HOLX)

EP Wealth Advisors LLC bought a new position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 9,956 shares of the medical equipment provider's stock, valued at approximately $811,000.

Other hedge funds have also recently made changes to their positions in the company. Cetera Investment Advisers grew its stake in shares of Hologic by 188.9% in the 1st quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider's stock valued at $1,595,000 after buying an additional 13,380 shares during the period. Andra AP fonden raised its holdings in shares of Hologic by 224.5% in the 2nd quarter. Andra AP fonden now owns 95,400 shares of the medical equipment provider's stock worth $7,083,000 after purchasing an additional 66,000 shares during the period. Swedbank AB raised its holdings in Hologic by 5.2% during the 2nd quarter. Swedbank AB now owns 1,630,440 shares of the medical equipment provider's stock valued at $121,060,000 after acquiring an additional 80,575 shares during the period. GAMMA Investing LLC raised its holdings in Hologic by 17.9% during the 3rd quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider's stock valued at $312,000 after acquiring an additional 582 shares during the period. Finally, Quest Partners LLC raised its holdings in Hologic by 56.1% during the 2nd quarter. Quest Partners LLC now owns 41,492 shares of the medical equipment provider's stock valued at $3,081,000 after acquiring an additional 14,914 shares during the period. 94.73% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, COO Essex D. Mitchell sold 24,856 shares of the business's stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 1.75% of the company's stock.

Hologic Price Performance

Shares of HOLX traded down $1.30 during trading hours on Wednesday, reaching $75.53. 3,159,135 shares of the stock traded hands, compared to its average volume of 1,617,876. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a 52-week low of $68.15 and a 52-week high of $84.67. The company's 50-day moving average price is $79.62 and its two-hundred day moving average price is $78.60. The company has a market cap of $17.14 billion, a P/E ratio of 23.07, a price-to-earnings-growth ratio of 2.37 and a beta of 0.96.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting the consensus estimate of $1.01. The business had revenue of $987.90 million for the quarter, compared to analysts' expectations of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business's quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.89 EPS. On average, analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HOLX has been the subject of several research reports. Needham & Company LLC reiterated a "buy" rating and issued a $90.00 target price on shares of Hologic in a research report on Tuesday. Royal Bank of Canada increased their price target on shares of Hologic from $86.00 to $89.00 and gave the stock a "sector perform" rating in a research note on Tuesday, November 5th. Evercore ISI increased their price target on shares of Hologic from $78.00 to $82.00 and gave the stock an "in-line" rating in a research note on Tuesday, October 1st. StockNews.com raised shares of Hologic from a "hold" rating to a "buy" rating in a research note on Thursday, November 14th. Finally, Citigroup cut shares of Hologic from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $95.00 to $85.00 in a report on Tuesday, October 1st. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, Hologic currently has a consensus rating of "Moderate Buy" and an average price target of $89.50.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.